Efficacy of fronto-temporal transcranial direct current stimulation for refractory auditory verbal hallucinations in schizophrenia: A randomized, double-blind, sham-controlled study

Persistent auditory verbal hallucinations (AVH) that are refractory to antipsychotic medications are reported in about 20–30% of schizophrenia patients. Transcranial Direct Current Stimulation (tDCS), a non-invasive and safe neuromodulatory technique, has attracted significant interest as an add-on...

Full description

Saved in:
Bibliographic Details
Published in:Schizophrenia research 2018-05, Vol.195, p.475-480
Main Authors: Bose, Anushree, Shivakumar, Venkataram, Agarwal, Sri Mahavir, Kalmady, Sunil V., Shenoy, Sonia, Sreeraj, Vanteemar S., Narayanaswamy, Janardhanan C., Venkatasubramanian, Ganesan
Format: Article
Language:English
Subjects:
Adolescent
Adult
Analysis of Variance
Auditory hallucinations
Double-Blind Method
Female
Frontal Lobe - physiology
Hallucinations - etiology
Hallucinations - therapy
Humans
Male
Middle Aged
Psychiatric Status Rating Scales
Schizophrenia
Schizophrenia - complications
tDCS
Temporal Lobe - physiology
Transcranial Direct Current Stimulation - methods
Treatment Outcome
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Persistent auditory verbal hallucinations (AVH) that are refractory to antipsychotic medications are reported in about 20–30% of schizophrenia patients. Transcranial Direct Current Stimulation (tDCS), a non-invasive and safe neuromodulatory technique, has attracted significant interest as an add-on treatment for refractory AVH in schizophrenia. Studies examining the efficacy of tDCS for refractory AVH in schizophrenia have reported inconsistent findings. In this study, using a randomized, double-blind, sham-controlled design (RCT), we sought to examine the effect of add-on tDCS [anode corresponding to left dorsolateral prefrontal cortex and cathode to left temporo-parietal junction; 2-mA, twice-daily sessions for 5-days] to treat refractory AVH in schizophrenia patients (N=25); following this RCT phase, patients that had
ISSN:0920-9964
1573-2509
DOI:10.1016/j.schres.2017.08.047